Imbalances persisted in medical history (diabetes mellitus, hypertension) and the use of MRAs/SGLT-2 inhibitors across groups, which likely stemmed from both the inherent comorbidity burden and renal function-dependent therapeutic restrictions (e.g., renal-adjusted dosing guidelines for MRAs/SGLT-2i). Here, SLC5A2 is linked to hypertensive disorder.